Application of cell therapy in the treatment of chronic and degenerative lesions in patients with rheumatoid arthritis
DOI:
https://doi.org/10.62305/biosana.v4i3.150Keywords:
rheumatoid arthritis; cellular therapy; mesenchymal stem cells; stem cellsAbstract
Rheumatoid Arthritis (RA) is a chronic systemic disease of autoimmune nature that, thanks to advances in the understanding of immune and inflammatory mechanisms, has driven the development of therapies that offer new hope to patients suffering from incurable diseases, in which current therapeutic approaches focus on symptom control and not on curing the disease. The objective of this research is to carry out a bibliographic review on the application of cell therapy in the treatment of chronic and degenerative lesions in patients with Rheumatoid Arthritis, through a critical analysis of current and high-impact evidence to infer a better therapeutic approach in our setting. A bibliographic review of the existing scientific literature was carried out regarding the application of cell therapy in the treatment of chronic and degenerative lesions in patients with Rheumatoid Arthritis. In medical bibliography databases: PubMed, The New England Journal of Medicine, Scopus, Elsevier´s ScienceDirect, Directory of Open Access Journals. Science Direct, Mendeline, Cochranre and Scielo that support the information and allow the fulfillment of the objectives set. Considered as a new innovative treatment strategy, cell therapy takes advantage of its special characteristics of renewing and differentiating, to regenerate damaged tissues and cells of the human body. The types of cells used in cell therapy protocols depend on the clinical purpose that is intended to be given to them. MSCs are stem cells with the ability to perform immunosuppressive functions in the cells of the immune system, both innate and adaptive. According to these clinical trials, mesenchymal stem cell therapy may be suitable for patients with RA, safely and effectively reducing joint pain and swelling as well as improving joint function.
Downloads
References
Lopez-Santalla M, Bueren JA, Garin MI. Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies. EBioMedicine. 2021;69.
Razantsava Leibuk E. Nuevos enfoques terapéuticos para el tratamiento de la Artritis Reumatoide mediante inmunomodulación con células madre mesenquimales: desde la terapia celular hasta la terapia libre de células. 2023.
Cáceres JA, Cando KM. Actividad de la enfermedad relacionada con calidad de vida y adherencia al tratamiento en pacientes con artritis reumatoide. Hospital IESS-Cuenca, 2019: Universidad de Cuenca; 2020.
MSP. Artritis reumatoide. Guía de Práctica Clínica (GPC). In: Gob.ec., editor. Primera edición:16–252016.
Zaripova LN, Midgley A, Christmas SE, Beresford MW, Pain C, Baildam EM, et al. Mesenchymal Stem Cells in the Pathogenesis and Therapy of Autoimmune and Autoinflammatory Diseases. International Journal of Molecular Sciences. 2023;24(22):16040.
Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PloS one. 2012;7(5):e35296.
Li Y-J, Chen Z. Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Therapeutic advances in musculoskeletal disease. 2022;14:1759720X221100294.
Lee B-W, Kwok S-K. Mesenchymal Stem/Stromal Cell-Based Therapies in Systemic Rheumatic Disease: From Challenges to New Approaches for Overcoming Restrictions. International Journal of Molecular Sciences. 2023;24(12):10161.
Rantapää‐Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism. 2003;48(10):2741-9.
De Bari C. Are mesenchymal stem cells in rheumatoid arthritis the good or bad guys? Arthritis research & therapy. 2015;17:1-9.
Patel JP, Srinivasa NKK, Gande A, Anusha M, Dar H, Baji DB. The role of biologics in rheumatoid arthritis: a narrative review. Cureus. 2023;15(1).
Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE, et al. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis research & therapy. 2015;17:1-8.
Sarsenova M, Issabekova A, Abisheva S, Rutskaya-Moroshan K, Ogay V, Saparov A. Mesenchymal stem cell-based therapy for rheumatoid arthritis. International journal of molecular sciences. 2021;22(21):11592.
Hwang JJ, Rim YA, Nam Y, Ju JH. Recent developments in clinical applications of mesenchymal stem cells in the treatment of rheumatoid arthritis and osteoarthritis. Frontiers in Immunology. 2021;12:631291.
Harna B, Kalra P, Arya S, Jeyaraman N, Nallakumarasamy A, Jeyaraman M, et al. Mesenchymal stromal cell therapy for patients with rheumatoid arthritis. Experimental Cell Research. 2023;423(1):113468.
Radu A-F, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.
Hoang DM, Pham PT, Bach TQ, Ngo AT, Nguyen QT, Phan TT, et al. Stem cell-based therapy for human diseases. Signal transduction and targeted therapy. 2022;7(1):1-41.
El-Kadiry AE-H, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Frontiers in Medicine. 2021;8:756029.
Peng Y, Jiang H, Zuo H-D. Factors affecting osteogenesis and chondrogenic differentiation of mesenchymal stem cells in osteoarthritis. World Journal of Stem Cells. 2023;15(6):548.
Liu H, Li R, Liu T, Yang L, Yin G, Xie Q. Immunomodulatory effects of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles in rheumatoid arthritis. Frontiers in Immunology. 2020;11:1912.
Moghaddam MZ, Mousavi MJ, Ghotloo S. Cell‐based therapies for the treatment of rheumatoid arthritis. Immunity, Inflammation and Disease. 2023;11(11):e1091.
Shimizu Y, Ntege EH, Azuma C, Uehara F, Toma T, Higa K, et al. Management of Rheumatoid Arthritis: Possibilities and Challenges of Mesenchymal Stromal/Stem Cell-Based Therapies. Cells. 2023;12(14):1905.
Mueller A-L, Payandeh Z, Mohammadkhani N, Mubarak SM, Zakeri A, Alagheband Bahrami A, et al. Recent advances in understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells. 2021;10(11):3017.
Breitman M, Bonfield TL, Caplan AI, Lazarus HM, Haghiac M, LaSalvia S, et al. Optimization of human mesenchymal stem cells for rheumatoid arthritis: implications for improved therapeutic outcomes. ACR Open Rheumatology. 2022;4(2):152-60.
Huang J, Fu X, Chen X, Li Z, Huang Y, Liang C. Promising therapeutic targets for treatment of rheumatoid arthritis. Frontiers in immunology. 2021;12:686155.
Lopez-Santalla M, Fernandez-Perez R, Garin MI. Mesenchymal stem/stromal cells for rheumatoid arthritis treatment: an update on clinical applications. Cells. 2020;9(8):1852.
Mesa LE, López JG, López Quiceno L, Barrios Arroyave F, Halpert K, Camacho JC. Safety and efficacy of mesenchymal stem cells therapy in the treatment of rheumatoid arthritis disease: A systematic review and meta-analysis of clinical trials. Plos one. 2023;18(7):e0284828.
Luque-Campos N, Contreras-López RA, Jose Paredes-Martinez M, Torres MJ, Bahraoui S, Wei M, et al. Mesenchymal stem cells improve rheumatoid arthritis progression by controlling memory T cell response. Frontiers in immunology. 2019;10:798.
El-Jawhari JJ, El-Sherbiny Y, McGonagle D, Jones E. Multipotent mesenchymal stromal cells in rheumatoid arthritis and systemic lupus erythematosus; from a leading role in pathogenesis to potential therapeutic saviors? Frontiers in Immunology. 2021;12:643170.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 BIOSANA Health Scientific Journal. ISSN 2960-8481
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
